Production (Stage)
Cytophage Technologies Ltd.
CYTO.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -808.40K | -887.60K | -798.70K | -911.20K | -3.18M |
| Total Depreciation and Amortization | 177.50K | 127.40K | 130.20K | 126.60K | 132.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.30K | 36.00K | -6.60K | -18.40K | 1.98M |
| Change in Net Operating Assets | 107.30K | 183.50K | 40.00K | 44.00K | -501.30K |
| Cash from Operations | -507.30K | -540.80K | -635.20K | -759.10K | -1.56M |
| Capital Expenditure | -2.20K | -71.50K | -266.60K | -569.20K | -46.20K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -160.70K | 0.00 | 0.00 | 5.82M |
| Cash from Investing | -2.20K | -232.20K | -266.60K | -569.20K | 5.78M |
| Total Debt Issued | -- | 225.00K | -- | -- | -- |
| Total Debt Repaid | -74.60K | 27.70K | -74.60K | -100.60K | -113.60K |
| Issuance of Common Stock | -- | -- | 0.00 | 5.00K | 2.50M |
| Repurchase of Common Stock | -- | -2.50M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 2.50M | 0.00 | 0.00 | -2.53M |
| Cash from Financing | -52.00K | 180.50K | -54.70K | -69.90K | -105.60K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -561.40K | -592.50K | -956.50K | -1.40M | 4.11M |